

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

**APPROVAL FOR CLINICAL TRIAL OF THE GROUP'S PRODUCT
TUL01101 TABLETS**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that on 8 September 2023, the application for the clinical trial of class 1 new drug TUL01101 Tablets submitted by Zhuhai United Laboratories Co., Ltd., a wholly-owned subsidiary of the Company, was approved by China National Medical Products Administration, with reference numbers of CXHL2300701 and CXHL2300702.

TUL01101 Tablets is a small molecular JAK1 (tyrosine kinase) selective inhibitor for the treatment of moderate to severe atopic dermatitis (AD). JAK inhibitors are new therapeutic drugs for AD with the advantages of definite curative effect and less side effects. Up to now, no JAK1 inhibitor independently developed by Chinese company has been approved for marketing.

Focusing on JAK1 target, the Company has been approved and is conducting clinical trials of topical preparations for moderate to severe active rheumatoid arthritis and mild to moderate AD. The approval of this new oral dosage form is expected to provide relevant patients with a more comprehensive, safe and effective new treatment option.

The Company is committed to continue research and development of new products, which is expected to create more values for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 8 September 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.